pharmaceutical daily

Sanofi investing €350 million for new vaccine factory in Canada

Image is for illustration purposes only. Source: NIH

Sanofi is investing €350 million for the construction of a new vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. 

David Loew, Executive Vice President and Head of Sanofi Pasteur said that Canada has a strong legacy in the research and development of vaccines and that with this investment, Sanofi is renewing its longstanding commitment to making Canada central in its effort to protect and improve human health across the globe. “Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease,” he said.
Sanofi said that the new facility will allow it’s vaccines global business unit meeting the growing demand of five-component acellular pertussis (5-acP) antigen. Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines, the company said.
Noting that this project is one of the most important investments for the Sanofi global industrial network, Philippe Luscan, who is Executive Vice President, Global Industrial Affairs, Sanofi, said: “It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world.” 
Exit mobile version